Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could regrow hair in severe alopecia – trial begins

NCT ID NCT07617597

Disease control Sponsor: Sun Pharma Japan Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 5 times

Summary

This study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied patients are with their hair. It is a Phase 3, placebo-controlled study with an open-label extension, meaning all participants can receive the drug later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent has been obtained. * Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent. * Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months. * SALT score of 50 or more at both Screening and Baseline. Exclusion Criteria: * Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization. * Treatment with biologics within 6 months prior to Screening. * Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening. * History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography. * Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Study Site 101

    NOT_YET_RECRUITING

    Hamamatsu, 431-3192, Japan

  • Study Site 102

    NOT_YET_RECRUITING

    Asahikawa, 078-8510, Japan

  • Study Site 103

    RECRUITING

    Sapporo, 060-8648, Japan

  • Study Site 104

    RECRUITING

    Niigata, 951-8520, Japan

  • Study Site 105

    RECRUITING

    Shinjuku-Ku, 160-0023, Japan

  • Study Site 106

    RECRUITING

    Mitaka-shi, 181-8611, Japan

  • Study Site 107

    NOT_YET_RECRUITING

    Kyoto, 606-8507, Japan

  • Study Site 108

    RECRUITING

    Osaka, 545-0051, Japan

  • Study Site 109

    RECRUITING

    Osaka, 542-0081, Japan

  • Study Site 110

    NOT_YET_RECRUITING

    Kurashiki, 701-0192, Japan

  • Study Site 111

    RECRUITING

    Ube, 755-8505, Japan

  • Study Site 112

    RECRUITING

    Kitakyushu, 807-8556, Japan

  • Study Site 113

    NOT_YET_RECRUITING

    Kurume, 830-0011, Japan

  • Study Site 114

    NOT_YET_RECRUITING

    Miyagi-gun, 981-0112, Japan

  • Study Site 116

    RECRUITING

    Ishikawa, 920-0293, Japan

  • Study Site 117

    NOT_YET_RECRUITING

    Bunkyō City, 113-8431, Japan

  • Study Site 118

    NOT_YET_RECRUITING

    Kōtoku, 136-0075, Japan

  • Study Site 119

    NOT_YET_RECRUITING

    Ebina, 243-0432, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.